Zantac Medication Poses a Greater Risk

Zantac and its generic form are being pulled off the shelves at all stores. The FDA has determined the low levels of a cancer-causing chemical is a greater risk than they previously thought.

Previously, the FDA had said they detected low levels of a cancer-causing chemical in a sampling of the medication. However, they felt patients could continue using the medication and did not face any serious health risks.

Today, the FDA is telling stores to immediately pull the medication and its generic form off the shelves. Patients should stop taking the medications right away.

The FDA has determined that the contamination issue within the medication poses a greater threat than previously thought.

Zantac, the brand-name version of the drug, is sold by Sanofi, but generic versions are sold by many.

According to the FDA, Ranitidine is a histamine blocker that works to lower the acid created in the stomach.  Zantac and Ranitidine are often prescribed to prevent ulcers of the stomach and intestines as well as gastroesophageal reflux disease.

The FDA released that it had found low levels of a cancer-causing contaminant, a type of nitrosamine called nitrosodimethylamine, or NDMA, in the heartburn medications.

The FDA is continuing to investigate the source of contamination as well at the potential risk this has to consumers.

Recovering compensation after an injury from a defective product

It is a manufacturer’s responsibility to make sure their products are safe for consumers.  If someone is injured due to a defective product, a product liability claim may exist.  A claim may be pursued to pay for damages caused by the defective product such as medical bills, missed time from work and pain and suffering.

If you or someone you know has been seriously injured by a defective product, it is important to contact a personal injury attorney to review your rights.  Call 412-661-1400 to schedule a free consultation with a personal injury lawyer in Pittsburgh at Berger and Green today.

Source: The New York Times, “Zantac heartburn drug recalled on contamination risk”